Atherogenic Lipid Profiles and Cardiovascular Risk Indices in Epilepsy: A Retrospective Study

Abstract

Objective: Epilepsy is increasingly recognized as a condition associated with elevated cardiovascular risk, potentially influenced by both the disease itself and long-term antiseizure medication (ASM) use. Atherogenic lipid indices enable a more detailed evaluation of cardiovascular risk that may not be evident through conventional lipid measurements. Methods: In this retrospective analysis, 71 patients with epilepsy and 50 age- and sex-matched healthy individuals were recruited from the Neurology and Cardiology outpatient departments of Siirt Training and Research Hospital between January 1, 2024, and January 1, 2025. According to the criteria established by the International League Against Epilepsy (ILAE), patients were classified into two subgroups: drug-sensitive epilepsy (DSE, n=52) and drug-resistant epilepsy (DRE, n=19). Demographic, clinical, and biochemical data were collected. Atherogenic indices were calculated and compared across groups. The relationships between treatment duration and lipid-based risk indicators were examined using correlation analysis and multivariate linear regression, accounting for potential covariates. Results: Compared with healthy controls, the DRE group exhibited significantly lower high-density lipoprotein cholesterol (HDL-C) levels (p=0.030) and higher Castelli Risk Index II (CRI-II) values (p=0.01). In multivariate regression models, longer epilepsy duration and higher body mass index (BMI) were independently associated with increased CRI-II (p=0.023 and p=0.003, respectively) and Cholesterol Index (CHOLIndex) (p=0.026 and p=0.009, respectively). Conclusions: Epilepsy patients, particularly those with DRE or prolonged treatment duration, demonstrate unfavorable shifts in lipid-based cardiovascular risk markers.

Keywords

• Epilepsy
• Atherogenic index of plasma
• CHOLIndex
• Cardiovascular risk
• Antiseizure medications
• Drug resistant

References

1. Gaertner ML, Mintzer S, DeGiorgio CM. Increased cardiovascular risk in epilepsy. Front Neurol. 2024;15:1339276. doi:10.3389/fneur.2024.1339276.
2. Vivanco‐Hidalgo RM, Gomez A, Moreira A, Díez L, Elosua R, Roquer J. Prevalence of cardiovascular risk factors in people with epilepsy. Brain Behav. 2017;7(2):e00618. doi:10.1002/brb3.618.
3. Terman SW, Aubert CE, Hill CE, Skvarce J, Burke JF, Mintzer S. Cardiovascular disease risk, awareness, and treatment in people with epilepsy. Epilepsy Behav. 2021;117:107878.
4. Nei M, Ho J, Ho RT. Cardiovascular effects of antiseizure medications for epilepsy. CNS Drugs. 2025;1-19. doi:10.1007/s40263-025-01163-x.
5. Płonka-Półtorak E, Zagrodzki P, Kryczyk-Kozioł J, Westermarck T, Kaipainen P, Kaski M, et al. Does valproate therapy in epileptic patients contribute to changing atherosclerosis risk factors? the role of lipids and free fatty acids. Pharmacol Rep. 2016;68:1339-44. doi:10.1016/j.pharep.2016.09.001.
6. Zuberi NA, Baig M, Bano S, Batool Z, Haider S, Perveen T. Assessment of atherosclerotic risk among patients with epilepsy on valproic acid, lamotrigine, and carbamazepine treatment. Neurosci J. 2017;22(2):114-8. doi:10.17712/nsj.2017.2.20160342.
7. Khot SS, Shaikh MH, Gupta L. Atherosclerotic risk among epileptic patients taking carbamazepine, phenytoin treatment: brief review. Int J Pharm Sci Res. 2013;4(3):900-6. doi:10.13040/IJPSR.0975-8232.4(3).900-06.
8. Talaat FM, Kamel T, Rabah AM, Ahmed SM, El-Jaafary SI, Abdelaziz GH. Epilepsy and antiepileptic drugs: risk factors for atherosclerosis. Int J Neurosci. 2015;125(7):507-11. doi:10.3109/00207454.2014.949704.

9. Nikolaos T, Stylianos G, Chryssoula N, Irini P, Christos M, Dimitrios T, et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit. 2004;10(4):MT50-MT52.
10. Bhardwaj S, Bhattacharjee J, Bhatnagar MK, Tyagi S, Delhi N. Atherogenic index of plasma, castelli risk index and atherogenic coefficient-new parameters in assessing cardiovascular risk. Int J Pharm Biol Sci. 2013;3(3):359-64.
11. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77. doi:10.1111/j.1528-1167.2009.02397.x.
12. Cardenas-Rodriguez N, Huerta-Gertrudis B, Rivera-Espinosa L, Montesinos-Correa H, Bandala C, Carmona-Aparicio L, et al. Role of oxidative stress in refractory epilepsy: evidence in patients and experimental models. Int J Mol Sci. 2013;14(1):1455-76. doi:10.3390/ijms14011455.
13. Yadav R, Liu Y, Kwok S, Hama S, France M, Eatough R, et al. Effect of extended-release niacin on High-Density Lipoprotein (HDL) functionality, lipoprotein metabolism, and mediators of vascular inflammation in statin-treated patients. J Am Heart Assoc. 2015; 15:4(9):e001508. doi:10.1161/jaha.114.001508.
14. Muller AL, Diaz-Arias L, Cervenka MC, McDonald TJ. The effect of anti-seizure medications on lipid values in adults with epilepsy. Epilepsy Behav. 2023;144:109260. doi:10.1016/j.yebeh.2023.109260.
15. Vyas MV, Davidson BA, Escalaya L, Costella J, Saposnik G, Burneo JG. Antiepileptic drug use for treatment of epilepsy and dyslipidemia: systematic review. Epilepsy Res. 2015;113:44-67. doi:10.1016/j.eplepsyres.2015.03.002.
16. Mintzer S, Skidmore CT, Abidin CJ, Morales MC, Chervoneva I, Capuzzi DM, et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol. 2009;65(4):448-56. doi:10.1002/ana.21615.
17. Lossius MI, Nakken KO, Mowinckel P, Taubøll E, Gjerstad L. Favorable change of lipid profile after carbamazepine withdrawal. Acta Neurol Scand. 2016;134(3):219-23. doi:10.1111/ane.12534.
18. Sareen S, Vyas R, Soni Y, Verma A. A prospective study of lipid profile changes in patients on anti-epileptic drug therapy. Int J Res Rev. 2019;6(9):123-7.
19. Mahrous DM, Moustafa AN, Higazi MM, Higazi AM, AbdelAziz RA. Influence of different antiseizure medications on vascular risk factors in children with epilepsy. Children. 2022;9(10):1499. doi:10.3390/children9101499.
20. Mahmoud AA, Aboelghar HM, Abdelmageed SM, Abdallah HM, Garib MI, Abd El Hady NM. Assessment of asymmetric dimethylarginine and homocysteine in epileptic children receiving antiepileptic drugs. Pediatr Res. 2022;92(6):1606-12. doi:10.1038/s41390-022-02132-6.
21. Lioy B, Webb RJ, Amirabdollahian F. The association between the atherogenic index of plasma and cardiometabolic risk factors: a review. Healthcare (Basel). 2023;11(7):966. doi:10.3390/healthcare11070966.
22. Nazish S. Obesity and metabolic syndrome in patients with epilepsy, their relation with epilepsy control. Ann Afr Med. 2023;22(2):136-44. doi:10.4103/aam.aam_139_22.
23. Attilakos A, Dinopoulos A, Tsirouda M, Paschalidou M, Prasouli A, Stamati A, et al. Effect of levetiracetam monotherapy on lipid profiles and thyroid hormones in children with epilepsy: a prospective study. Epilepsy Res. 2019;155:106162. doi:10.1016/j.eplepsyres.2019.106162.
24. Wang M, Wang M, Zhang Q, Zong S, Lv C. Pharmacokinetics and safety of levetiracetam extended-release tablets and relative bioavailability compared with immediate-release tablets in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 2018;43(4):405-13. doi:10.1007/s13318-018-0461-2.
25. Çetin İD, Demiral M. The effect of levetiracetam therapy on lipid profile in epileptic children. Anatol J Gen Med Res. 2023;33(3). 342-8. doi:10.4274/anatoljmed.2022.49765.
26. Özer G. Do antiepileptics have any potential to induce insulin resistance? A comparison between levetiracetam and valproic acid. Eur Res J. 2019;5(1):88-93. doi:10.18621/eurj.382538.
27. Janousek J, Barber A, Goldman L, Klein P. Obesity in adults with epilepsy. Epilepsy Behav. 2013;28(3):391-4. doi:10.1016/j.yebeh.2013.05.012.